Novel Animal Models of Pediatric Epilepsy

Neurotherapeutics

Volumn 9, Issue 2, 2012, Pages 245-261

  Auvin, Stéphane ^a,b,c   Pineda, Eduardo ^d   Shin, Don ^d   Gressens, Pierre ^a,b,c   Mazarati, Andrey ^d  

^a INSERM   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Animal models; Development; Epilepsy; Immature brain; Seizure

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BUMETANIDE; CORTICOTROPIN RELEASING FACTOR; DOXORUBICIN; GLUTAMATE TRANSPORTER; METHYLAZOXYMETHANOL ACETATE; N METHYL DEXTRO ASPARTIC ACID; PILOCARPINE; POTASSIUM CHANNEL KCNQ2; RETIGABINE; SODIUM CHANNEL NAV1.1; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; TETRODOTOXIN; TUBERIN;

ADULT DISEASE; BENIGN CHILDHOOD EPILEPSY; BRAIN DAMAGE; BRAIN DISEASE; BRAIN INJURY; BRAIN MATURATION; CORTICAL DYSPLASIA; DISEASE MODEL; DOWN SYNDROME; EPILEPTIC STATE; EPILEPTOGENESIS; GENE MUTATION; HOMEOBOX; HUMAN; HYPERTHERMIA; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INFANTILE SPASM; IRRADIATION; NONHUMAN; PATHOPHYSIOLOGY; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; TUBEROUS SCLEROSIS;

AGE FACTORS; ANIMALS; BRAIN; CHILD; DISEASE MODELS, ANIMAL; EPILEPSY; HUMANS;

EID: 84859713398     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0119-8     Document Type: Review

References (151)

1. Guerrini R. Epilepsy in children. Lancet 2006; 367: 499-524.
2. Berg AT, Berkovic SF, Brodie MJ, al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51: 676-685.
3. Fisher RS, van Emde BW, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46: 470-472.
4. ILAE. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 489-501.
5. ILAE. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30: 389-399.
6. Berg AT, Shinnar S, Levy SR, Testa FM. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia 1999; 40: 445-452.
7. King M, Newton M, Jackson G, et al. Epileptology of the first-seizure presentation: a clinical, electroencephalographic, and magnetic resonnance imaging study of 300 consecutive patients. Lancet 1998; 352: 1007-1011.
8. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. How well can epilepsy syndromes be identified at diagnosis? A reassessment 2 years after initial diagnosis. Epilepsia 2000; 41: 1269-1275.
9. Picot MC, Baldy-Moulinier M, Daures JP, Dujols P, Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population-based study in a Western European country. Epilepsia 2008; 49: 1230-1238.
10. Stafstrom CE, Sutula TP. Models of epilepsy in the developing and adult brain: implications for neuroprotection. Epilepsy Behav 2005; 7(suppl 3): S18-S24.
11. Jensen FE. Pediatric epilepsy models. Epilepsy Res 2006; 68: 28-31.
12. Engel J, Schwartzkroin PA. What should be modeled? In: Pitkanen A, Schwartzkroin PA, Moshe SL, eds. Models of seizures and epilepsy. Amsterdam: Elsevier, 2006: 1-14.
13. Stafstrom CE, Moshe SL, Swann JW, Nehlig A, Jacobs MP, Schwartzkroin PA. Models of pediatric epilepsies: startegies and opportunities. Epilepsia 2006; 47: 1407-1414.
14. Sarkisian MR. Overview of the current animal models for human seizure and epileptic disorders. Epilepsy Behav 2001; 2: 201-216.
15. Pitkanen A, Kharatishvili I, Karhunen H, et al. Epileptogenesis in experimental models. Epilepsia 2007; 48(suppl 2): 13-20.
16. Baram TZ, Jensen FE, Brooks-Kayal A. Does acquired epileptogenesis in the immature brain require neuronal death. Epilepsy Curr 2011; 11: 21-26.
17. Dudek FE, Ekstrand JJ, Staley KJ. Is neuronal death necessary for acquired epileptogenesis in the immature brain? Epilepsy Curr 2010; 10: 95-99.
18. Dubé C, Baram TZ. Complex febrile seizure-An experimental model in immature rodents. In: Pitkanen A, Schwartzkroin PA, Moshe SL, eds. Models of seizures and epilepsy. Oxford, UK: Elsevier, 2006: 333-340.
19. Wallace SJ. Epilepsy in cerebral palsy. Dev Med Child Neurol 2001; 43: 713-717.
20. Kadam SD, White AM, Staley KJ, Dudek FE. Continuous electroencephalographic monitoring with radio-telemetry in a rat model of perinatal hypoxia-ischemia reveals progressive post-stroke epilepsy. J Neurosci 2010; 30: 404-415.
21. Rakhade SN, Klein PM, Huynh T, et al. Development of later life spontaneous seizures in a rodent model of hypoxia-induced neonatal seizures. Epilepsia 2011; 52: 753-765.
22. Sankar R, Shin DH, Liu H, Mazarati A, Pereira de Vasconcelos, Wasterlain CG. Patterns of status epilepticus-induced neuronal injury during development and long-term consequences. J Neurosci 1998; 18: 8382-8393.
23. Raol YS, Budreck EC, Brooks-Kayal AR. Epilepsy after early-life seizures can be independent of hippocampal injury. Ann Neurol 2003; 53: 503-511.
24. Toth Z, Yan XX, Haftoglou S, Ribak CE, Baram TZ. Seizure-induced neuronal injury: vulnerability to febrile seizures in an immature rat model. J Neurosci 1998; 18: 4285-4294.
25. Bender RA, Dube C, Gonzalez-Vega R, Mina EW, Baram TZ. Mossy fiber plasticity and enhanced hippocampal excitability, without hippocampal cell loss or altered neurogenesis, in an animal model of prolonged febrile seizures. Hippocampus 2003; 13: 399-412.
26. Dubé C, Richichi C, Bender RA, Chung G, Litt B, Baram TZ. Temporal lobe epilepsy after experimental prolonged febrile seizures: prospective analysis. Brain 2006; 129: 911-922.
27. Dubé C, Ravizza T, Hamamura M, Qinqin Z, Keebaugh A, Fok K et al. Epileptogenesis provked by prolonged exêrimental febrile seizures: mechanisms and biomarkers. J Neurosci 2010; 30: 7484-7494.
28. Auvin S, Mazarati A, Shin D, Sankar R. Inflammation enhances epileptogenesis in the developing rat brain. Neurobiol Dis 2010; 40: 303-310.
29. Auvin S, Catteau B, Ganga-Zandzou PS, Ythier H. Atypical varicella with palm and sole involvement. Int J Dermatol 2002; 41: 903-905.
30. Auvin S, Vallee L. [Febrile seizures: current understanding of pathophysiological mechanisms]. Arch Pediatr 2009; 16: 450-456.
31. Ohtahara S, Yamatogi Y. Epileptic encephalopathies in early infancy with suppression-burst. J Clin Neurophysiol 2003; 20: 398-407.
32. Molinari F, Raas-Rothschild A, Rio M, et al. Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet 2005; 76: 334-339.
33. Milh M, Becq H, Villeneuve N, Ben-Ari Y, Aniksztejn L. Inhibition of glutamate transporters results in a "suppression-burst" pattern and partial seizures in the newborn rat. Epilepsia 2007; 48: 169-174.
34. Shimamoto K, Lebrun B, Yasuda-Kamatani Y, et al. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol 1998; 53: 195-201.
35. Watanabe K. West syndrome: etiological and pronosctic aspects. Brain Dev 1998; 20: 1-8.
36. Riikonen R. Infantile spasms: therapy and outcome. J Child Neurol 2004; 19: 401-404.
37. Rantala H, Putkonen T. Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut syndrome. Epilepsia 1999; 40: 286-289.
38. Riikonen R. Long-term otucome of West syndrome: a study of adults with a history of infantile spasms. Epilepsia 1996; 37: 367-372.
39. Koo B, Hwang PA, Logan WJ. Infantile spasms: outcome and prognostic factors of cryptogenic and symptomatic groups. Neurology 1993; 43: 2322-2327.
40. Brunson KL, Eghbal-Ahmadi M, Baram TZ. How do the many etiologies of West syndrome lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis. Brain Dev 2001; 23: 533-538.
41. Baram TZ, Schultz L. Corticotropin-releasing hormone is a rapid and potent convulsant in the infant rat. Brain Res Dev Brain Res 1991; 61: 97-101.
42. Baram TZ, Schultz L. ACTH does not control neonatal seizures induced by administration of exogenous corticotropin-releasing hormone. Epilepsia 1995; 36: 174-178.
43. Brunson KL, Khan N, Eghbal-Ahmadi M, Baram TZ. Corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression. Ann Neurol 2001; 49: 304-312.
44. Kabova R, Liptakova S, Slamberova R, Pometlova M, Velisek L. Age-specific N-methyl-D-aspartate-induced seizures: perspectives for the West syndrome model. Epilepsia 1999; 40: 1357-1369.
45. Mares P, Velisek L. N-methyl-D-aspartate (NMDA)-induced seizures in developing rats. Brain Res Dev Brain Res 1992; 65: 185-189.
46. Stafstrom CE, Sasaki-Adams DM. NMDA-induced seizures in developing rats cause long-term learning impairment and increased seizure susceptibility. Epilepsy Res 2003; 53: 129-137.
47. Yum MS, Chachua T, Veliskova J, Velisek L. Prenatal stress promotes development of spasms in infant rats. Epilepsia 2012; 53: e46-e49.
48. Chachua T, Yum MS, Veliskova J, Velisek L. Validation of the rat model of cryptogenic infantile spasms. Epilepsia 2011; 52: 1666-1677.
49. Velisek L, Jehle K, Asche S, Veliskova J. Model of infantile spasms induced by N-methyl-D-aspartic acid in prenatally impaired brain. Ann Neurol 2007; 61: 109-119.
50. Galvan CD, Hrachovy RA, Smith KL, Swann JW. Blockade of neuronal activity during hippocampal development produces a chronic focal epilepsy in the rat. J Neurosci 2000; 20: 2904-2916.
51. Galvan CD, Wenzel JH, Dineley KT, et al. Postsynaptic contributions to hippocampal network hyperexcitability induced by chronic activity blockade in vivo. Eur J Neurosci 2003; 18: 1861-1872.
52. Frost JD Jr., Lee CL, Hrachovy RA, Swann JW. High frequency EEG activity associated with ictal events in an animal model of infantile spasms. Epilepsia 2011; 52: 53-62.
53. Lee CL, Frost JD Jr., Swann JW, Hrachovy RA. A new animal model of infantile spasms with unprovoked persistent seizures. Epilepsia 2008; 49: 298-307.
54. Scantlebury MH, Galanopoulou AS, Chudomelova L, Raffo E, Betancourth D, Moshe SL. A model of symptomatic infantile spasms syndrome. Neurobiol Dis 2010; 37: 604-612.
55. Raffo E, Coppola A, Ono T, Briggs SW, Galanopoulou AS. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis 2011; 43: 322-329.
56. Ono T, Moshe SL, Galanopoulou AS. Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasms. Epilepsia 2011; 52: 1678-1684.
57. Galdzicki Z, Siarey RJ. Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes Brain Behav 2003; 2: 167-178.
58. Cortez MA, Shen L, Wu Y, et al. Infantile spasms and Down syndrome: a new animal model. Pediatr Res 2009; 65: 499-503.
59. Snead OC, III, Depaulis A, Vergnes M, Marescaux C. Absence epilepsy: advances in experimental animal models. Adv Neurol 1999; 79: 253-278.
60. Cortez MA, Sadeghnia HR, Aleem IS, et al. A new animal model of infantile spasms: ACTH and antiepileptic drug profiles. 2007; A211 Pediatr Res. 2009 May; 65(5): 499-503.
61. Stafstrom CE, Konkol RJ. Infantile spasms in children with Down syndrome. Dev Med Child Neurol 1994; 36: 576-585.
62. Auvin S, Lamblin MD, Pandit F, Vallee L, Bouvet-Mourcia A. Infantile epileptic encephalopathy with late-onset spasms: report of 19 patients. Epilepsia 2010; 51: 1290-1296.
63. Eisermann MM, Ville D, Soufflet C, O et al. Cryptogenic late-onset epileptic spasms: an overlooked syndrome of early childhood? Epilepsia 2006; 47: 1035-1042.
64. Eisermann MM, DeLaRaillere A, Dellatolas G, et al. Infantile spasms in Down syndrome - effects of delayed anticonvulsive treatment. Epilepsy Res 2003; 55: 21-27.
65. Hirose S, Mitsudome A. X-linked mental retardation and epilepsy: pathogenetic significance of ARX mutations. Brain Dev 2003; 25: 161-165.
66. Kitamura K, Yanazawa M, Sugiyama N, et al. Mutation of ARX causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. Nat Genet 2002; 32: 359-369.
67. Price MG, Yoo JW, Burgess DL, et al. A triplet repeat expansion genetic mouse model of infantile spasms syndrome, Arx(GCG)10+7, with interneuronopathy, spasms in infancy, persistent seizures, and adult cognitive and behavioral impairment. J Neurosci 2009; 29: 8752-8763.
68. Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 2011; 52: 158-174.
69. Hirabayashi S, Binnie CD, Janota I, Polkey CE. Surgical treatment of epilepsy due to cortical dysplasia: clinical and EEG findings. J Neurol Neurosurg Psychiatry 1993; 56: 765-770.
70. Francione S, Vigliano P, Tassi L, et al. Surgery for drug resistant partial epilepsy in children with focal cortical dysplasia: anatomical-clinical correlations and neurophysiological data in 10 patients. J Neurol Neurosurg Psychiatry 2003; 74: 1493-1501.
71. Russo GL, Tassi L, Cossu M, et al. Focal cortical resection in malformations of cortical development. Epileptic Disord 2003; 5(suppl 2): S115-S123.
72. Scantlebury MH, Ouellet PL, Psarropoulou C, Carmant L. Freeze lesion-induced focal cortical dysplasia predisposes to atypical hyperthermic seizures in the immature rat. Epilepsia 2004; 45: 592-600.
73. Baraban SC, Wenzel HJ, Hochman DW, Schwartzkroin PA. Characterization of heterotopic cell clusters in the hippocampus of rats exposed to methylazoxymethanol in utero. Epilepsy Res 2000; 39: 87-102.
74. Colacitti C, Sancini G, Franceschetti S, et al. Altered connections between neocortical and heterotopic areas in methylazoxymethanol-treated rat. Epilepsy Res 1998; 32: 49-62.
75. Castro PA, Cooper EC, Lowenstein DH, Baraban SC. Hippocampal heterotopia lack functional Kv4. 2 potassium channels in the methylazoxymethanol model of cortical malformations and epilepsy. J Neurosci 2001; 21: 6626-6634.
76. Tschuluun N, Jurgen WH, Doisy ET, Schwartzkroin PA. Initiation of epileptiform activity in a rat model of periventricular nodular heterotopia. Epilepsia 2011; 52: 2304-2314.
77. de Feo MR, Mecarelli O, Ricci GF. Seizure susceptibility in immature rats with micrencephaly induced by prenatal exposure to methylazoxymethanol acetate. Pharmacol Res 1995; 31: 109-114.
78. Chevassus-au-Louis N, Ben-Ari Y, Vergnes M. Decreased seizure threshold and more rapid rate of kindling in rats with cortical malformation induced by prenatal treatment with methylazoxymethanol. Brain Res 1998; 812: 252-255.
79. Setkowicz Z, Janicka D, Kowalczyk A, Turlej A, Janeczko K. Congenital brain dysplasias of different genesis can differently affect susceptibility to pilocarpine- or kainic acid-induced seizures in the rat. Epilepsy Res 2005; 67: 123-131.
80. Germano IM, Zhang YF, Sperber EF, Moshe SL. Neuronal migration disorders increase susceptibility to hyperthermia-induced seizures in developing rats. Epilepsia 1996; 37: 902-910.
81. Harrington EP, Moddel G, Najm IM, Baraban SC. Altered glutamate receptor - ctransporter expression and spontaneous seizures in rats exposed to methylazoxymethanol in utero. Epilepsia 2007; 48: 158-168.
82. Park KI, Chu K, Jung KH, et al. Role of cortical dysplasia in epileptogenesis following prolonged febrile seizure. Epilepsia 2010; 51: 1809-1819.
83. Choi IS, Cho JH, Lee MG, Choi BJ. Pilocarpine-induced seizure susceptibility in rats following prenatal methylazoxymethanol treatment. Biol Pharm Bull 2005; 28: 1408-1413.
84. Hicks SP, D'amato CJ. Low dose radiation of the developing brain. Science 1963; 141: 903-905.
85. Hossain M, Chetana M, Devi PU. Late effect of prenatal irradiation on the hippocampal histology and brain weight in adult mice. Int J Dev Neurosci 2005; 23: 307-313.
86. Roper SN. In utero irradiation of rats as a model of human cerebrocortical dysgenesis: a review. Epilepsy Res 1998; 32: 63-74.
87. Setkowicz Z, Majcher K, Janicka D, et al. Brains with different degrees of dysplasia show different patterns of neurodegenerative changes following pilocarpine-induced seizures. Histologic evidence of tissue damage correlated with MRI data. Neurol Res 2006; 28: 453-460.
88. Rosen GD, Burstein D, Galaburda AM. Changes in efferent and afferent connectivity in rats with induced cerebrocortical microgyria. J Comp Neurol 2000; 418: 423-440.
89. Hablitz JJ, DeFazio T. Excitability changes in freeze-induced neocortical microgyria. Epilepsy Res 1998; 32: 75-82.
90. Jacobs KM, Hwang BJ, Prince DA. Focal epileptogenesis in a rat model of polymicrogyria. J Neurophysiol 1999; 81: 159-173.
91. Zilles K, Qu MS, Kohling R, Speckmann EJ. Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: quantitative in vitro receptor autoradiography. Neuroscience 1999; 94: 1051-1061.
92. Redecker C, Luhmann HJ, Hagemann G, Fritschy JM, Witte OW. Differential downregulation of GABAA receptor subunits in widespread brain regions in the freeze-lesion model of focal cortical malformations. J Neurosci 2000; 20: 5045-5053.
93. Scantlebury MH, Gibbs SA, Foadjo B, Lema P, Psarropoulou C, Carmant L. Febrile seizures in the predisposed brain: a new model of temporal lobe epilepsy. Ann Neurol 2005; 58: 41-49.
94. Fauser S, Huppertz HJ, Bast T, et al. Clinical characteristics in focal cortical dysplasia: a retrospective evaluation in a series of 120 patients. Brain 2006; 129: 1907-1916.
95. Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003; 11: 1457-1466.
96. van Slegtenhorst M, Nellist M, Nagelkerken B, et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 1998; 7: 1053-1057.
97. Orlova KA, Crino PB. The tuberous sclerosis complex. Ann N Y Acad Sci 2010; 1184: 87-105.
98. Eker R. Familial renal adenomas in Wistar rats; a preliminary report. Acta Pathol Microbiol Scand 1954; 34: 554-562.
99. Eker R, Mossige J, Johannessen JV, Aars H. Hereditary renal adenomas and adenocarcinomas in rats. Diagn Histopathol 1981; 4: 99-110.
100. Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR, Knudson AG. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci U S A 1994; 91: 11413-11416.
101. Yeung RS, Katsetos CD, Klein-Szanto A. Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis. Am J Pathol 1997; 151: 1477-1486.
102. Wenzel HJ, Patel LS, Robbins CA, Emmi A, Yeung RS, Schwartzkroin PA. Morphology of cerebral lesions in the Eker rat model of tuberous sclerosis. Acta Neuropathol 2004; 108: 97-108.
103. Kwiatkowski DJ, Zhang H, Bandura JL, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002; 11: 525-534.
104. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999; 59: 1206-1211.
105. Kobayashi T, Minowa O, Sugitani Y, et al. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci U S A 2001; 98: 8762-8767.
106. Young DM, Schenk AK, Yang SB, Jan YN, Jan LY. Altered ultrasonic vocalizations in a tuberous sclerosis mouse model of autism. Proc Natl Acad Sci U S A 2010; 107: 11074-11079.
107. Uhlmann EJ, Apicelli AJ, Baldwin RL, et al. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells. Oncogene 2002; 21: 4050-4059.
108. Uhlmann EJ, Wong M, Baldwin RL, et al. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol 2002; 52: 285-296.
109. Wong M, Ess KC, Uhlmann EJ, et al. Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Ann Neurol 2003; 54: 251-256.
110. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008; 63: 444-453.
111. Zeng LH, Rensing NR, Zhang B, Gutmann DH, Gambello MJ, Wong M. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet 2011; 20: 445-454.
112. Wang Y, Greenwood JS, Calcagnotto ME, Kirsch HE, Barbaro NM, Baraban SC. Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1. Ann Neurol 2007; 61: 139-152.
113. Meikle L, Talos DM, Onda H, et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 2007; 27: 5546-5558.
114. Racine RJ. Modification of seizure activity by electrical stimulation: cortical areas. Electroencephalogr Clin Neurophysiol 1975; 38: 1-12.
115. Moshe SL. The effects of age on the kindling phenomenon. Dev Psychobiol 1981; 14: 75-81.
116. Moshe SL, Albala BJ. Kindling in developing rats: persistence of seizures into adulthood. Brain Res 1982; 256: 67-71.
117. Lothman EW, Hatlelid JM, Zorumski CF, Conry JA, Moon PF, Perlin JB. Kindling with rapidly recurring hippocampal seizures. Brain Res 1985; 360: 83-91.
118. Michelson HB, Lothman EW. An ontogenetic study of kindling using rapidly recurring hippocampal seizures. Brain Res Dev Brain Res 1991; 61: 79-85.
119. Sankar R, Auvin S, Kwon Y, Pineda E, Shin D, Mazarati A. Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling. Epilepsia. 2010 Jul; 51 Suppl 3: 39-42.
120. Wang C, Shimizu-Okabe C, Watanabe K, et al. Developmental changes in KCC1, KCC2, and NKCC1 mRNA expressions in the rat brain. Brain Res Dev Brain Res 2002; 139: 59-66.
121. Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci 2002; 3: 728-739.
122. Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med 2005; 11: 1205-1213.
123. Dzhala VI, Brumback AC, Staley KJ. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. Ann Neurol 2008; 63: 222-235.
124. Mazarati A, Shin D, Sankar R. Bumetanide inhibits rapid kindling in neonatal rats. Epilepsia 2009; 50: 2117-2122.
125. Shah MM, Mistry M, Marsh SJ, Brown DA, Delmas P. Molecular correlates of the M-current in cultured rat hippocampal neurons. J Physiol 2002; 544: 29-37.
126. Okada M, Wada K, Kamata A, Murakami T, Zhu G, Kaneko S. Impaired M-current and neuronal excitability. Epilepsia 2002; 43(suppl 9): 36-38.
127. Singh NA, Westenskow P, Charlier C, et al. KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum. Brain 2003; 126: 2726-2737.
128. Qiu C, Johnson BN, Tallent MK. K + M-current regulates the transition to seizures in immature and adult hippocampus. Epilepsia 2007; 48: 2047-2058.
129. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000; 58: 253-262.
130. Mazarati A, Wu J, Shin D, Kwon YS, Sankar R. Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study. Epilepsia 2008; 49: 1777-1786.
131. Lothman EW, Bertram EH, III. Epileptogenic effects of status epilepticus. Epilepsia 1993; 34(suppl 1): S59-S70.
132. Lothman EW, Williamson JM. Closely spaced recurrent hippocampal seizures elicit two types of heightened epileptogenesis: a rapidly developing, transient kindling and a slowly developing, enduring kindling. Brain Res 1994; 649: 71-84.
133. Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011; 52(suppl 2): 3-9.
134. Dravet C, Bureau M, Dalla BB, Guerrini R. Severe myoclonic epilepsy in infancy (Dravet syndrome) 30 years later. Epilepsia 2011; 52(suppl 2): 1-2.
135. Catterall WA. Ion channel voltage sensors: structure, function, and pathophysiology. Neuron 2010; 67: 915-928.
136. Depienne C, Trouillard O, Saint-Martin C, et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet 2009; 46: 183-191.
137. Oakley JC, Kalume F, Yu FH, Scheuer T, Catterall WA. Temperature- and age-dependent seizures in a mouse model of severe myoclonic epilepsy in infancy. Proc Natl Acad Sci U S A 2009; 106: 3994-3999.
138. Ogiwara I, Miyamoto H, Morita N, et al. Nav1. 1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 2007; 27: 5903-5914.
139. Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome. Epilepsia 2011; 52(suppl 2): 44-49.
140. Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006; 9: 1142-1149.
141. Kalume F, Yu FH, Westenbroek RE, Scheuer T, Catterall WA. Reduced sodium current in Purkinje neurons from Nav1. 1 mutant mice: implications for ataxia in severe myoclonic epilepsy in infancy. J Neurosci 2007; 27: 11065-11074.
142. Dutton SB, Sawyer NT, Kalume F, et al. Protective effect of the ketogenic diet in Scn1a mutant mice. Epilepsia 2011; 52: 2050-2056.
143. Caraballo RH, Cersosimo RO, Sakr D, Cresta A, Escobal N, Fejerman N. Ketogenic diet in patients with Dravet syndrome. Epilepsia 2005; 46: 1539-1544.
144. Korff C, Laux L, Kelley K, Goldstein J, Koh S, Nordli D Jr. Dravet syndrome (severe myoclonic epilepsy in infancy): a retrospective study of 16 patients. J Child Neurol 2007; 22: 185-194.
145. Nabbout R, Copioli C, Chipaux M, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia 2011; 52: e54-e57.
146. van Luijtelaar EL, Drinkenburg WH, van Rijn CM, Coenen AM. Rat models of genetic absence epilepsy: what do EEG spike-wave discharges tell us about drug effects? Methods Find Exp Clin Pharmacol 2002; 24(suppl D): 65-70.
147. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39: 508-512.
148. Burke JF, Mogg AE. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res 1985; 13: 6265-6272.
149. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2: 467-469.
150. Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997; 3: 1280-1284.
151. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999; 104: 375-381.